Syndax PharmaceuticalsFRA:1T3 -3.98%25 Gross Margin % is 95.94% as of Mar. 2026, which is 0% below its 10-year median of 96.24. GuruFocus rates FRA:1T3 with a GF Score™ of 25/100. The stock has 7 warning signs investors should review. Among 733 Biotechnology companies, Syndax Pharmaceuticals ranks better than 93.86% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Syndax Pharmaceuticals had a gross margin of 95.94% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Syndax Pharmaceuticals Gross Margin % Related Terms
Syndax Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Syndax Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1T3 vs IOVA, GLUE, TYRA: Gross Margin % Comparison
For the Biotechnology subindustry, Syndax Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syndax Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Syndax Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Syndax Pharmaceuticals (FRA:1T3) has a Gross Margin % of 95.94% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Syndax Pharmaceuticals and its competitors. This is near median its historical median of 96.24. Over the past decade, Syndax Pharmaceuticals' Gross Margin % has ranged from 95.96 to 96.51. According to the industry distribution chart, Syndax Pharmaceuticals ranks #45 out of 733 companies in the Biotechnology industry, placing it in the top 6.1%.
Is Syndax Pharmaceuticals' Gross Margin % too high?
Syndax Pharmaceuticals' current Gross Margin % of 95.94% is near median its 10-year median of 96.24. Over the past 10 years, this metric has ranged from a low of 95.96 to a high of 96.51. The Biotechnology industry median Gross Margin % is 60.90. Syndax Pharmaceuticals' value of 95.94% is 57.5% above this industry median. Based on the distribution chart, Syndax Pharmaceuticals ranks #45 out of 733 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Syndax Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Gross Margin % compare to IOVA and GLUE?
According to the Biotechnology industry distribution chart, Syndax Pharmaceuticals ranks #45 out of 733 companies for Gross Margin %. This places Syndax Pharmaceuticals in the top 6% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.90. Syndax Pharmaceuticals' value of 95.94% is 57.5% above this benchmark. Historically, Syndax Pharmaceuticals' own Gross Margin % has ranged from 95.96 to 96.51 over the past decade. While the company's 10-year median is 96.24 vs. the industry median of 60.90, Syndax Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syndax Pharmaceuticals's current Gross Margin % of 95.94% is 57.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Syndax Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syndax Pharmaceuticals's current Gross Margin % is 95.94%, which is near median its own 10-year median of 96.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current Gross Margin % of 95.94%. The current Gross Margin % is 95.94%, which is near median its 10-year median of 96.24 and 57.5% above the Biotechnology industry median of 60.90. Syndax Pharmaceuticals' overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current Gross Margin % is 95.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
25GF Score
Get the complete analysis for FRA:1T3
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1T3 has been successfully added to your 
